Explore

Trendline Trendline
Rznomics Joins Lilly Gateway Labs to Accelerate RNA Therapeutic Development

Rznomics Joins Lilly Gateway Labs to Accelerate RNA Therapeutic Development

Rznomics Joins Lilly Gateway Labs to Accelerate RNA Therapeutic Development
Rapid Read Rapid Read
LUNGevity Foundation Highlights Patient Perspectives on Liquid Biopsy in Precision Oncology for Lung Cancer

LUNGevity Foundation Highlights Patient Perspectives on Liquid Biopsy in Precision Oncology for Lung Cancer

Nikki Martin, Senior Director of Precision Medicine Initiatives at the LUNGevity Foundation, presented a webinar focusing on patient-centered perspectives regarding liquid biopsy within precision oncology for lung cancer. The presentation delved into various aspects, including patients' understanding of biomarker testing, their access to liquid biopsy technologies, communication challenges, and the role of liquid biopsy in guiding treatment selection and access to clinical trials. Key findings indicate that patients desire active participation in their care decisions and seek a foundational understanding of biomarker testing, often asking what biomarkers are, their importance, and if they are inheritable. Despite recognizing practical benefits like minimally invasive sampling and faster turnaround times, significant barriers to biomarker testing persist, particularly among underserved populations. There is also wide variability in patient understanding of liquid biopsy, with some interpreting it literally ...
Rapid Read Rapid Read
GSK's Jemperli Receives Priority Review from FDA for Locally Advanced Rectal Cancer

GSK's Jemperli Receives Priority Review from FDA for Locally Advanced Rectal Cancer

The U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab), a drug developed by GSK. This application targets patients with previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer. The FDA has set a PDUFA action date for February 2027. The application is also eligible for expedited review through the National Priority Voucher program, potentially leading to an earlier FDA decision. This submission is supported by positive data from the registrational phase II, single-arm AZUR-1 trial, which demonstrated a significant and sustained clinical complete response rate for 12 months, meaning no detectable signs of cancer for at least one year. The safety profile of dostarlimab in this trial was consistent with its known and manageable safety profile observed in other solid tumors. Jemperli was previously granted Fast Track and Breakt...
Rapid Read Rapid Read
NASA-Funded Project Develops Edible Cookies from Upcycled Plastic and Plant Waste

NASA-Funded Project Develops Edible Cookies from Upcycled Plastic and Plant Waste

Scientists at Southern Illinois University (SIU) Carbondale, funded by NASA, have developed a method to create edible, protein-rich cookies from upcycled plastic bottles and plant waste. This innovative process uses specially designed yeasts to convert polyethylene terephthalate (PET) plastic and agricultural biomass into proteins, fats, and flavorings. The PET plastic is first broken down into carbon-rich molecules using an oxidative hydrothermal dissolution process, which involves water and oxygen at high temperature and pressure. These molecules are then fed to genetically programmed yeasts, which transform them into new biological molecules. The resulting mixture is combined with fiber, starch, and sweeteners, and then extruded through a 3D printer to form 'µBites' (microbites). While taste tests are pending institutional approval, the cookies have received high marks for aroma. This research is part of NASA's Deep Space Food Challenge, aiming to create sustainable food sources for astronauts on long-d...
Trendline Trendline
McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Clinical Research and Commercialization Services

McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Clinical Research and Commercialization Services

McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding Clinical Research and Commercialization Services
Trendline Trendline
Copia Scientific Partners with HSE•AG to Enhance North American Lab Automation with Nucleic Acid Quantification Solutions

Copia Scientific Partners with HSE•AG to Enhance North American Lab Automation with Nucleic Acid Quantification Solutions

Copia Scientific Partners with HSE•AG to Enhance North American Lab Automation with Nucleic Acid Quantification Solutions
USA Today USA Today
Case map and graphs capture resurgence of disease once eliminated in the US

Case map and graphs capture resurgence of disease once eliminated in the US

Graphics show how measles cases have surged to the highest level in decades
Lubbock Avalanche-Journal Lubbock Avalanche-Journal
Texas Tech aims to shine bringing Global Sorghum Conference to Lubbock

Texas Tech aims to shine bringing Global Sorghum Conference to Lubbock

Sitting among one of the largest sorghum-growing areas in the U.S., Texas Tech aims to show the world how its cutting-edge research and innovation can drive an industry.
Trendline Trendline
Neurocrine Biosciences Receives FDA IND Acceptance for Alzheimer's Cognition Drug Phase 2 Study

Neurocrine Biosciences Receives FDA IND Acceptance for Alzheimer's Cognition Drug Phase 2 Study

Neurocrine Biosciences Receives FDA IND Acceptance for Alzheimer's Cognition Drug Phase 2 Study
Trendline Trendline
Scientists Develop Algae-Based System to Reduce Lab-Grown Meat Production Costs by Up to 90%

Scientists Develop Algae-Based System to Reduce Lab-Grown Meat Production Costs by Up to 90%

Scientists Develop Algae-Based System to Reduce Lab-Grown Meat Production Costs by Up to 90%
Rapid Read Rapid Read
Engineered Probiotic Bacteria Show Promise in Regulating Blood Sugar for Diabetes Management

Engineered Probiotic Bacteria Show Promise in Regulating Blood Sugar for Diabetes Management

Scientists from the Shanghai Academy of Natural Sciences (SANS) in China have developed an oral living drug, named GIFT, which utilizes engineered probiotic bacteria to detect and respond to high blood sugar levels. These bacteria, specifically a modified strain of Escherichia coli Nissle 1917 (EcN), are equipped with a built-in molecular glucose sensor. When ingested, the probiotics temporarily colonize the intestine. Upon detecting blood sugar levels rising above a normal threshold, the sensor activates therapeutic genes within the bacteria, prompting them to produce and release GLP-1, a hormone that stimulates insulin release to lower blood sugar. The system is designed to automatically cease hormone production once blood sugar returns to a healthy range. This innovative approach aims to provide precise, on-demand dosing, addressing a limitation of current diabetes injections like semaglutide, which deliver a constant, high dose and can lead to adverse reactions. Experiments in diabetic mice showed sign...
TheStreet TheStreet
A cancer vaccine years in the making just proved itself

A cancer vaccine years in the making just proved itself

Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.